A detailed history of Hudson Canyon Capital Management transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Hudson Canyon Capital Management holds 2,319 shares of REGN stock, worth $2.67 Million. This represents 1.65% of its overall portfolio holdings.

Number of Shares
2,319
Previous 2,626 11.69%
Holding current value
$2.67 Million
Previous $2.53 Billion 3.57%
% of portfolio
1.65%
Previous 1.63%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

SELL
$883.2 - $1071.19 $271,142 - $328,855
-307 Reduced 11.69%
2,319 $2.44 Billion
Q4 2023

Jan 26, 2024

SELL
$775.18 - $881.7 $44,185 - $50,256
-57 Reduced 2.12%
2,626 $2.31 Billion
Q2 2023

Aug 02, 2023

SELL
$700.03 - $830.35 $58,802 - $69,749
-84 Reduced 3.04%
2,683 $1.93 Billion
Q1 2023

Aug 02, 2023

SELL
$680.49 - $826.97 $97,990 - $119,083
-144 Reduced 4.95%
2,767 $2.27 Billion
Q4 2022

Aug 02, 2023

SELL
$705.89 - $766.39 $115,765 - $125,687
-164 Reduced 5.33%
2,911 $2.1 Billion
Q3 2022

Aug 02, 2023

SELL
$573.97 - $724.32 $177,930 - $224,539
-310 Reduced 9.16%
3,075 $2.12 Billion
Q2 2022

Aug 02, 2023

SELL
$548.35 - $738.84 $162,859 - $219,435
-297 Reduced 8.07%
3,385 $2 Billion
Q4 2021

Aug 02, 2023

BUY
$543.48 - $670.97 $106,522 - $131,510
196 Added 5.62%
3,682 $2.33 Billion
Q3 2021

Aug 02, 2023

SELL
$574.03 - $680.96 $72,901 - $86,481
-127 Reduced 3.52%
3,486 $2.11 Billion
Q2 2021

Aug 02, 2023

SELL
$472.8 - $558.54 $5,673 - $6,702
-12 Reduced 0.33%
3,613 $2.02 Billion
Q1 2021

Aug 02, 2023

BUY
$446.73 - $548.2 $122,850 - $150,755
275 Added 8.21%
3,625 $1.72 Billion
Q4 2020

Aug 02, 2023

BUY
$478.3 - $607.98 $1.6 Million - $2.04 Million
3,350 New
3,350 $1.62 Billion

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $123B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Hudson Canyon Capital Management Portfolio

Follow Hudson Canyon Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Canyon Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Canyon Capital Management with notifications on news.